Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes.
暂无分享,去创建一个
Ross T Tsuyuki | S. Majumdar | Jeffrey A. Johnson | R. Tsuyuki | D. Eurich | Sumit R Majumdar | Jeffrey A Johnson | Dean T Eurich
[1] D. Singer,et al. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. , 2001, The American journal of medicine.
[2] P. Sleight. Angiotensin II and trials of cardiovascular outcomes. , 2002, The American journal of cardiology.
[3] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[4] R. Hayward,et al. Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care , 2003, Annals of Internal Medicine.
[5] A. Maggioni,et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. , 1997, Circulation.
[6] K. Teo,et al. NITROGLYCERIN AS AN INDICATOR FOR THE PRESENCE OF CORONARY HEART DISEASE , 1999 .
[7] Pierre Ernst,et al. The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .
[8] D. Grobbee,et al. Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus. , 2002, Journal of clinical epidemiology.
[9] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[10] P. Beck,et al. Health Databases in Saskatchewan , 2002 .
[11] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[12] W. Tierney,et al. Comparing methods to identify general internal medicine clinic patients with chronic heart failure. , 2001, American heart journal.
[13] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[14] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[15] P. Parfrey,et al. Community pharmacist outreach program directed at physicians treating congestive heart failure. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[16] L. Køber,et al. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. , 1999, Journal of the American College of Cardiology.
[17] Gregory E. Simon,et al. A Chronic Disease Score with Empirically Derived Weights , 1995, Medical care.
[18] W A Ray,et al. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. , 1989, JAMA.
[19] P. Passmore,et al. The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross‐sectional study in general practice , 2002, Pharmacoepidemiology and drug safety.
[20] S. Majumdar,et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. , 2002, Diabetes care.
[21] S. Yusuf,et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.
[22] G. Nichols,et al. Replicating the chronic disease score (CDS) from automated pharmacy data. , 1994, Journal of clinical epidemiology.
[23] E H Wagner,et al. A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.
[24] Lawrence A Leiter,et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[25] Andrew M. Johanos. The use of betaagonists and the risk of death and near death from asthma: Spitzer WO, Suissa S, Ernst P, et al N Engl J Med 326:501–506 Feb 1992 , 1992 .
[26] L. Køber,et al. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. , 1999, Journal of the American College of Cardiology.
[27] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[28] R. Pauwels,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.
[29] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.